There is a current ongoing trial (NCT02159495) where patients are being administered autologous anti-CD123 CAR-T cells for patients with CD123+ relapsed or refractory AML or CD123+ persistent or recurrent Blastic Plasmacytoid Dendritic Cell Neoplasm (69). This evidence concerns the gene IL3RA and acute myeloid leukemia.